Dr. Sébastien Bonnet

Dr. Bonnet is an Associate Professor in the Faculty of Medicine at Université Laval, Fellow of the American Heart Association and researcher at the IUCPQ Research Centre. In collaboration with Dr. Steeve Provencher, he founded and co-directs the Groupe de recherche en hypertension pulmonaire.

Dr. Bonnet's work has led to the discovery of the mechanism that causes pulmonary arterial hypertension. His team has also identified two substances with the potential to effectively treat this disease.

Dr. Bonnet's group uses a multidisciplinary and translational approach (from gene to population) to study the molecular and cellular mechanisms involved in the development of vascular (PAH and coronary) and bronchial remodeling processes. This work has led to the identification of new risk markers, improving the identification and management of individuals suffering from PAH.

His work has also led to the identification of new therapeutic targets such as Pim-1, miR-204 and PARP-1 in PAH. In addition, much of the work carried out in Dr. Bonnet's laboratory is aimed at assessing the impact of these targets in coronary artery disease, which shares many similarities with PAH.

The creation, by Drs Bonnet and Provencher, of the Pulmonary Hypertension Research Group, offers new prospects for PAH research. Indeed, the combination of Dr Bonnet's fundamental and pre-clinical research with Dr Provencher's clinical research means that research projects can now be carried out from the laboratory to the patient's bedside, which will undoubtedly speed up the discovery of new therapies.